◼ Archived
Business
🔮 fades ✓
AbbVie to Acquire Apogee Therapeutics, Deepening Immunology Portfolio
AbbVie is expanding its immunology portfolio through a nearly $11 billion acquisition of Apogee Therapeutics.
2 trends tracked about this subject — the full history, oldest to newest below.
AbbVie is expanding its immunology portfolio through a nearly $11 billion acquisition of Apogee Therapeutics.
AbbVie is reportedly nearing an $11 billion acquisition of biotech firm Apogee Therapeutics to secure an experimental eczema treatment.